^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Trailblaze Pharos™

    Company:
    Roche
    Type:
    CE Marked
    Related tests:
    Evidence Level:
    Sensitive: C4 – Case Studies

    [TPR-NTRK1 fusion-Pancreatic Cancer-entrectinib]

    Source:
    J Clin Oncol
    Test:

    Trailblaze Pharos™

    Title:
    Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer
    Excerpt:
    A TPR-NTRK1 fusion (Fig 1) was detected by NGS (Trailblaze Pharos Assay, Ignyta, San Diego, CA). He began receiving entrectinib on September 20, 2016. Immediately after initiating treatment, the patient experienced clinical benefit.
    DOI:
    10.1200/PO.18.00039
    Trial ID:
    STARTRK-2